Role of nitric oxide in pathophysiology and treatment of pulmonary hypertension
Language English Country United States Media print
Document type Journal Article
PubMed
25189396
DOI
10.1016/b978-0-12-800254-4.00016-7
PII: B978-0-12-800254-4.00016-7
Knihovny.cz E-resources
- Keywords
- NO inhalation, Nitric oxide, Nitric oxide synthase, Pathophysiology, Pulmonary hypertension, Therapy,
- MeSH
- Antihypertensive Agents pharmacology therapeutic use MeSH
- Humans MeSH
- Nitric Oxide metabolism MeSH
- Hypertension, Pulmonary drug therapy metabolism physiopathology MeSH
- Nitric Oxide Synthase Type III metabolism MeSH
- Vasodilation physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antihypertensive Agents MeSH
- Nitric Oxide MeSH
- Nitric Oxide Synthase Type III MeSH
Pulmonary hypertension is a condition characterized by vasoconstriction, vascular cell proliferation, inflammation, microthrombosis, and vessel wall remodelation. Pulmonary endothelial cells produce vasoactive substances with vasoconstrictive as well as vasodilatative effects. The imbalance of these endothelium-derived vasoactive substances induced by endothelial dysfunction is very important in the pathogenesis of PH. One of most important substances with vasodilatative effect is nitric oxide. We provide a comprehensive insight into role of NO in the pathgenesis of PH and discuss perspectives and challenges in PH therapy based on NO administration.
References provided by Crossref.org